Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms
NCT07684170
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
58
Enrollment
INDUSTRY
Sponsor class
Conditions
Neuroendocrine Neoplasm
Neuroendocrine Carcinomas
Neuroendocrine Tumors
Interventions
DRUG:
CTX-471
Sponsor
Compass Therapeutics